{
    "N/R/U": null,
    "Applicant": "Eli Lilly and Company",
    "BLA Number": "761215",
    "Proprietary Name": "Rezvoglar",
    "Proper Name": "insulin glargine-aglr",
    "BLA Type": "351(k) Interchangeable",
    "Strength": "300UNITS/3ML (100UNITS/ML)",
    "Dosage Form": "Injection ",
    "Route of Administration": "Subcutaneous",
    "Product Presentation": "Autoinjector",
    "Marketing Status": "Rx",
    "Licensure": "Licensed",
    "Approval Date": "17-Dec-21",
    "Ref. Product Proper Name": "insulin glargine",
    "Ref. Product Proprietary Name": "Lantus",
    "Supplement Number": null,
    "Submission Type": "Original",
    "License Number": "1891",
    "Product Number": "1",
    "Center": "CDER",
    "Date of First Licensure": null,
    "Exclusivity Expiration Date": null,
    "First Interchangeable Exclusivity Exp. Date": null,
    "Ref. Product Exclusivity Exp. Date": null,
    "Orphan Exclusivity Exp. Date": null,
    "drug": [
        {
            "name": "insulin glargine-aglr",
            "drugbank_id": "DB00047"
        }
    ]
}